Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...
Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC characterization.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...
Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive ...
A biotechnology and AI-enabled drug discovery company based in the San Francisco Bay Area, California. The company operates a ...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
Virtual clinical trials and digital twins are emerging approaches to understanding mechanisms of drug responses and drug treatment heterogeneity. With the goal of providing the right drug at the right ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results